uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained encouraging, the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and whether the therapy’s earlier benefits can demonstrate durability over time.
uniQure shares plunged after four-year data for Huntington’s gene therapy AMT-130 showed weaker disease-progression slowing than earlier results. While 48-month TFC data remained encouraging, the cUHDRS effect was not statistically significant. Investors are now focused on FDA review and whether the therapy’s earlier benefits can demonstrate durability over time.
<iframe src="https://hindustansphere.com/embed/cluster/f8245ecdc15b9fc533b32c48f498eacb8d2b9500" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Why uniQure shares are sinking after AMT-130 update"></iframe>
